TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36341835

Group type: EXPERIMENTAL
Intervention: 20 min HIIE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 min MICE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 min HIIE
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reading control intervention
Number of subjects: 40
Study: 36122501

Group type: EXPERIMENTAL
Intervention: Lentil-based meals (300 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lentil-based meals (600 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (0 g lentils)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lentil-based meals (300 g and 600 g)
Number of subjects: 30
Study: 34235222

Group type: EXPERIMENTAL
Intervention: 3D printed AFO with Somos NeXt
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3D printed AFO with PA12
Number of subjects: 15
Study: 35092891

Group type: EXPERIMENTAL
Intervention: TPTD 20 μg daily for an average of 6.1 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPTD 20 μg daily
Number of subjects: 0
Study: 32554035

Group type: EXPERIMENTAL
Intervention: Computer network-based feedback program
Number of subjects: 163
Study: 34890537

Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a primary third dose 2 months after the second dose (cohort 1a-14d-2m)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a booster dose 8 months after the second dose (cohort 1b-14d-8m)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a booster dose 8 months after the second dose (cohort 2b-28d-8m)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a primary third dose 2 months after the second dose (cohort 2a-28d-2m)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 1.5 μg, 3 μg, or 6 μg doses of CoronaVac, administered as a third dose 8 months after the second dose in adults aged 60 years and older
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 600
Study: 33936066

Group type: EXPERIMENTAL
Intervention: Higher circulating levels of IL‐2Rα
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating IL‐1Ra
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other ILs
Number of subjects: 0
Study: 35679283

Group type: EXPERIMENTAL
Intervention: JITAI group (personalized just‐in‐time adaptive intervention)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (Fitbit® without personalized feedback)
Number of subjects: 240
Study: 33818442

Group type: EXPERIMENTAL
Intervention: ropivacaine (40 mL/0.5%) + dexmedetomidine (1 μg/kg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ropivacaine (40 mL/0.5%) + fentanyl (1 μg/kg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ropivacaine (40 mL/0.5%) + verapamil (2.5 mg)
Number of subjects: 105
Study: 32301412

Group type: EXPERIMENTAL
Intervention: Safety behaviours (SBs)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No safety behaviours (control)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both conditions (SBs and no SBs)
Number of subjects: 111
Study: 33220526

Group type: EXPERIMENTAL
Intervention: 9-minute withdrawal time
Number of subjects: 1027

Group type: COMPARATOR
Intervention: 6-minute withdrawal time
Number of subjects: 1027
Study: 33476571

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (100 μg subcutaneously every 2 weeks) on top of phlebotomy and low-dose aspirin (100 mg daily)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Phlebotomy (300 mL per session to maintain haematocrit <45%) and low-dose aspirin (100 mg daily)
Number of subjects: 127
Study: 35686634

Group type: EXPERIMENTAL
Intervention: Myo-inositol (2000 mg) plus 400 μg folic acid daily from 14-24 gestational weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (400 μg of folic acid daily from 14-24 gestational weeks)
Number of subjects: 60
Study: 32568134

Group type: EXPERIMENTAL
Intervention: PEEP = 5 cm H2O (group P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PEEP = 0 cm H2O (group C)
Number of subjects: 40
Study: 36153034

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 33657259

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment (n = 31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate ointment (n = 32)
Number of subjects: 63
Study: 32643359

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 61
Study: 36195945

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (containing Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 42
Study: 34702331

Group type: EXPERIMENTAL
Intervention: Urodynamics and comprehensive clinical assessment
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Comprehensive clinical assessment only
Number of subjects: 1096
Study: 32944407

Group type: EXPERIMENTAL
Intervention: SVILE regimen
Number of subjects: 103

Group type: COMPARATOR
Intervention: P-GemOx regimen
Number of subjects: 103
Study: 35100429

Group type: EXPERIMENTAL
Intervention: Nicotine patch (NIC) 21 mg, daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo patch (PBO)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nicotine patch (NIC)
Number of subjects: 35
Study: 34427556

Group type: EXPERIMENTAL
Intervention: JBS3 lifetime risk calculator
Number of subjects: 173

Group type: COMPARATOR
Intervention: QRISK2 10-year risk calculator
Number of subjects: 173
Study: 33306247

Group type: EXPERIMENTAL
Intervention: DAA treatment for <4 weeks in patients with F0-F3 liver fibrosis
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: DAA treatment for <8 weeks in patients with liver cirrhosis
Number of subjects: 365
Study: 33079022

Group type: EXPERIMENTAL
Intervention: Garlic virus B (GarV-B) detection using RT-PCR and ELISA
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Testing of 30 garlic germplasm accessions for GarV-B using RT-PCR
Number of subjects: 5
Study: 35694835

Group type: EXPERIMENTAL
Intervention: casein phosphopeptide‐amorphous calcium fluoride phosphate (CPP‐ACFP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: self‐assembling peptide (P11‐4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: sodium fluoride (NaF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: artificial saliva (AS)
Number of subjects: 40
Study: 34534909

Group type: EXPERIMENTAL
Intervention: DTA model based on MRI findings
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: DTA model
Number of subjects: 357
Study: 32592261

Group type: COMPARATOR
Intervention: Control (CON; 20℃, 50% rH, FiO2 : 20.9%; sea level)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoxia (HYP; 20℃, 50% rH, FiO2 : 14.5%; a simulated altitude of 3,000 m)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hot (HOT; 35℃, 50% rH, FiO2 : 20.9%; sea level)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hot + Hypoxia (HH; 35℃, 50% rH, FiO2 : 14.5%; a simulated altitude of 3,000 m)
Number of subjects: 10
Study: 34293998

Group type: EXPERIMENTAL
Intervention: Music selected by the patient (n=35)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Music selected by the physician (n=36)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no music, n=35)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Patients answering in Arabic
Number of subjects: 106
Study: 32975853

Group type: EXPERIMENTAL
Intervention: Acylated ghrelin infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 36461123

Group type: EXPERIMENTAL
Intervention: Expectation-optimised video with patients giving information about their mostly positive therapy outcomes (positive model)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Video with instructions to focus on differences (discrepancy group)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Video with instructions to focus on similarities (similarity group)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group watched a video with patients giving information about their symptoms
Number of subjects: 158
Study: 34569641

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 33252379

Group type: EXPERIMENTAL
Intervention: Albuvirtide plus ritonavir-boosted lopinavir (ABT group)
Number of subjects: 175

Group type: COMPARATOR
Intervention: WHO-recommended second-line treatment (NRTI group)
Number of subjects: 175

Group type: COMPARATOR
Intervention: NRTI group (specifically those receiving tenofovir disoproxil fumarate)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both groups (ABT and NRTI)
Number of subjects: 175
Study: 33829710

Group type: EXPERIMENTAL
Intervention: BCG (19 times)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: BCG (15 times)
Number of subjects: 93

Group type: COMPARATOR
Intervention: EPI (18 times)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: BCG groups (combined)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CUETO scoring model and EORTC risk tables
Number of subjects: 93
Study: 32228533

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Locally-developed stress reduction intervention (LSR)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 71
Study: 33271298

Group type: EXPERIMENTAL
Intervention: Hypocaloric high-protein diet + fennel (2 capsule/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hypocaloric standardize diet + fennel (2 capsule/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hypocaloric high-protein diet + placebo
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hypocaloric standardize diet + placebo
Number of subjects: 64
Study: 32371987

Group type: EXPERIMENTAL
Intervention: TPN discontinuation at 100 ml/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: TPN discontinuation at 140 ml/kg/day
Number of subjects: 0
Study: 34921934

Group type: EXPERIMENTAL
Intervention: Symptom Assessment and Management Intervention (SAMI)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 179
Study: 34159620

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion (group DEX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion combined with vatinoxan 130 µg kg−1 followed by 40 µg kg−1 h−1 infusion (group VAT)
Number of subjects: 12
Study: 32778721

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Training (HIIT)
Number of subjects: 20
Study: 35234561

Group type: EXPERIMENTAL
Intervention: ROSE-010 100 µg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: ROSE-010 300 µg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 33475844

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescent cholangiography (NIFC) with preoperative administration of indocyanine green (ICG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of specific standardized steps for NIFC
Number of subjects: 0
Study: 32859156

Group type: EXPERIMENTAL
Intervention: StayFitLonger programme (experimental intervention)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 128
Study: 35508427

Group type: EXPERIMENTAL
Intervention: Mandala coloring for 30 min during premedication before chemotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 84
Study: 33638143

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network analysis on stone clearance rate in training group (813 cases)
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network analysis on stone clearance rate in testing group (270 cases)
Number of subjects: 1182
Study: 32815423

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral semaglutide 7 or 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral semaglutide
Number of subjects: 0
Study: 36069505

Group type: EXPERIMENTAL
Intervention: 5 ml ropivacaine 0.5%
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20 ml ropivacaine 0.5%
Number of subjects: 16
Study: 33750239

Group type: EXPERIMENTAL
Intervention: Fear-associated human chemosignals (three doses)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Neutral sweat
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fear-associated human chemosignals
Number of subjects: 67
Study: 35609214

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Community living after rehabilitation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Independent walking
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wheelchair use
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Walking speed improvement
Number of subjects: 60
Study: 33893329

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation of the left ventrolateral PFC (1.5 mA for 20 min)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Concurrent bilateral stimulation of the ventrolateral PFC (regardless of polarity direction)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Excitatory stimulation of occipital cortex
Number of subjects: 246
Study: 32839029

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg/h for 30 min before the end of surgery) in groups DD (Dex), ID (Dex), and II(Dex)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (II) without dexmedetomidine
Number of subjects: 210
Study: 35580961

Group type: EXPERIMENTAL
Intervention: Tapered shaped double‐threaded design (TS/DT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cylindrical shaped single‐threaded design (CS/ST)
Number of subjects: 28
Study: 32375501

Group type: EXPERIMENTAL
Intervention: Standardized minimal acupuncture at LI4 for 5 seconds (group A, n=48)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Semi-standardized individual acupuncture with a maximum of five insertions for up to 30 seconds (group B, n=49)
Number of subjects: 147

Group type: COMPARATOR
Intervention: No acupuncture (group C, n=48)
Number of subjects: 147
Study: 32622074

Group type: COMPARATOR
Intervention: Ultrasonic scaling (US) with usual oral hygiene instructions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with ultrasonic scaling (US)
Number of subjects: 22
Study: 36451150

Group type: EXPERIMENTAL
Intervention: Intravenous esketamine, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Number of subjects: 0
Study: 34169628

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Carbon-assisted Q-switched Nd: YAG laser treatment
Number of subjects: 80
Study: 36372958

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 70
Study: 32201062

Group type: EXPERIMENTAL
Intervention: L‐PRF membrane
Number of subjects: 32

Group type: COMPARATOR
Intervention: Spontaneous healing (Control)
Number of subjects: 32
Study: 33351452

Group type: EXPERIMENTAL
Intervention: Single preoperative 500 mg dose of methylprednisolone
Number of subjects: 151
Study: 34351377

Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: hrHPV testing at 12 months
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: hrHPV type-specific persistence at 12-month follow-up
Number of subjects: 354

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 354
Study: 32969128

Group type: EXPERIMENTAL
Intervention: Patients treated for localised prostate cancer
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group from the general population
Number of subjects: 287
Study: 33032868

Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 440

Group type: COMPARATOR
Intervention: Informational video
Number of subjects: 440

Group type: COMPARATOR
Intervention: No message
Number of subjects: 440
Study: 36111475

Group type: EXPERIMENTAL
Intervention: Robot group (87 cases, PKP assisted by modified orthopedic robot)
Number of subjects: 155

Group type: COMPARATOR
Intervention: C-arm group (68 cases, PKP assisted by C-arm X-ray fluoroscopy)
Number of subjects: 155
Study: 33054012

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed electrotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robotic mechanotherapy
Number of subjects: 0
Study: 35210126

Group type: EXPERIMENTAL
Intervention: Concentrated growth factor (CGF) applied to the mental nerve on one side
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no CGF applied)
Number of subjects: 26
Study: 32180528

Group type: EXPERIMENTAL
Intervention: Coping with depression program (individual psychoeducation based on the Neuman systems model, involving cognitive behavioral therapy techniques) administered at six sessions
Number of subjects: 0
Study: 33725408

Group type: EXPERIMENTAL
Intervention: Low immunosuppression (LI) with tacrolimus monotherapy
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: E+ patients (received SOC)
Number of subjects: 167
Study: 33415860

Group type: EXPERIMENTAL
Intervention: Tiaoyi Sanjiao acupuncture and moxibustion
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conventional Chinese and Western medicine (Control)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Comparison between treatment and control groups
Number of subjects: 154
Study: 35169165

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GLP-1(7-36)-amide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GLP-1/GIP combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34788325

Group type: EXPERIMENTAL
Intervention: Appropriate empirical antibiotic treatment
Number of subjects: 509

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 509
Study: 35700592

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (120 mg/d)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 32544416

Group type: EXPERIMENTAL
Intervention: Function Acquisition Speed Test (FAST) assessments
Number of subjects: 16
Study: 37553030

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg every 12 weeks
Number of subjects: 897
Study: 33646989

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 128
Study: 33353912

Group type: EXPERIMENTAL
Intervention: 10% citric acid-modified 2% chlorhexidine (CAmCHX)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 10% CAmCHX
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 1%, 6%, and 10% CAmCHX
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 6% and 10% CAmCHX
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 53

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 53
Study: 35679030

Group type: EXPERIMENTAL
Intervention: Marine ω-3 fatty acids, 1 g per day
Number of subjects: 23523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23523
Study: 33636278

Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy with external beam radiation therapy (RT) for 6 months
Number of subjects: 64
Study: 36180323

Group type: EXPERIMENTAL
Intervention: Bilateral paresthesia coverage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral paresthesia coverage
Number of subjects: 30
Study: 33331182

Group type: EXPERIMENTAL
Intervention: Sitafloxacin 100-mg once-daily for 3-5 days (acute uncomplicated UTI)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Sitafloxacin 100-mg twice daily for 10-14 days (complicated UTI)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Levofloxacin 500-mg once-daily for 3-5 days (acute uncomplicated UTI)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Levofloxacin 500-mg once-daily for 10-14 days (complicated UTI)
Number of subjects: 135
Study: 35995816

Group type: EXPERIMENTAL
Intervention: Antithrombin administration to maintain a level of 80-120%
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no antithrombin supplementation)
Number of subjects: 46
Study: 33430604

Group type: EXPERIMENTAL
Intervention: Heparin plus eptifibatide
Number of subjects: 13229

Group type: COMPARATOR
Intervention: Otamixaban
Number of subjects: 13229
Study: 32386891

Group type: EXPERIMENTAL
Intervention: Nitrate-rich vegetables
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 30
Study: 36418930

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonsmokers (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both smokers and nonsmokers (before and after treatment)
Number of subjects: 34
Study: 32485623

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 136
Study: 34789008

Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 33706830

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 1090

Group type: COMPARATOR
Intervention: No writing
Number of subjects: 1090